SMS Lifesciences India Limited — Important, 12-02-2025: Financial Result Updates

**Consolidated Financial Results Summary**

SMS Lifesciences India Limited reported a strong performance for the quarter ending December 31, 2024. Total revenue from operations reached ₹8,460.10 crore, marking a notable increase of approximately 3.5% from ₹8,205.33 crore in the same quarter last year. This growth can be attributed to heightened demand for Active Pharmaceutical Ingredients (APIs) and operational efficiencies initiated in previous quarters.

Net profit for the quarter amounted to ₹485.31 crore, up from ₹412.32 crore year-over-year, resulting in an Earnings Per Share (EPS) of ₹18.08. Improved profit margins were influenced by better cost management, particularly in manufacturing and employee expenses, which saw increases of 19.76% and 9.72%, respectively.

Total expenses rose to ₹7,774.13 crore, driven by escalating costs of materials consumed and manufacturing expenses. The firm managed to mitigate some inflationary pressures, reflecting effective cost control measures amidst rising operational costs.

The balance sheet appears robust with cash reserves indicating strong liquidity, supporting future growth initiatives. The consolidated entity recently concluded a successful USFDA inspection for its subsidiary, denoting a positive regulatory outlook.

Investor sentiment may lean towards a **buy** given the performance trends, strategic positioning in the pharma sector, and overall industry growth potential. Continued focus on innovation and market expansion could provide further upside.